Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 126, Issue 11, Pages 4119-4124Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI89067
Keywords
-
Categories
Funding
- NIH [CA50706, CA72597, P50-CA72012, P30-CA008748]
- Society of Memorial Sloan Kettering
- Byrne fund
- David Linn Family fund
- German Research Foundation (DFG) [NA 1133/1-1]
Ask authors/readers for more resources
Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability of thyroid cells to transport and accumulate iodide. Iodide uptake requires expression of critical genes that are involved in various steps of thyroid hormone biosynthesis. ERK signaling, which is markedly increased in thyroid cancer cells driven by oncogenic BRAF, represses the genetic program that enables iodide transport. Here, we determined that a critical threshold for inhibition of MAPK signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with Braf(V600E)-induced thyroid cancer. Although the MEK inhibitor selumetinib transiently inhibited ERK signaling, which subsequently rebounded, the MEK inhibitor CKI suppressed ERK signaling in a sustained manner by preventing RAF reactivation. A small increase in ERK inhibition markedly increased the expression of thyroid differentiation genes, increased iodide accumulation in cancer cells, and thereby improved responses to RAI therapy. Only a short exposure to the drug was necessary to obtain a maximal response to RAI. These data suggest that potent inhibition of ERK signaling is required to adequately induce iodide uptake and indicate that this is a promising strategy for the treatment of BRAF-mutant thyroid cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available